Abstracts tagged "C-reactive protein (CRP)"

Abstract Number: 560 • 2016 ACR/ARHP Annual Meeting
There Is No Further Gain from Calculating Disease Activity Score in 28 Joints with High Sensitivity Assays of C-Reactive Protein Because of High Intraindividual Variability of CRP: A Cross Sectional Study and Theoretical Consideration
Inger Marie J. Hansen^1,2,3, Rikke Asmussen⁴, Steen Antonsen⁵ and Amir Emamifar⁶, ¹Department of Reumatology, OUH, Svendborg Hospital, Svendborg, Denmark, ²University of Southern Denmark, 5000 Odense, Denmark, ³DANBIO, Glostrup, Denmark, ⁴Dep. of Rheumatology, OUH, Svendborg Hospital, Svendborg, Denmark, ⁵Biochemestry, OUH, Svendborg Hospital, 5700 Svendborg, Denmark, ⁶Rheumatology, OUH, Svendborg Hospital, 5700 Svendborg, Denmark
Background/Purpose: The threshold for reporting of C-reactive protein (CRP) differs from laboratory to laboratory. Moreover, CRP values are affected by the intra individual biological variability.[1]…
Abstract Number: 1415 • 2016 ACR/ARHP Annual Meeting
Impact of the Clinical Disease Activity Index to Treat to Target Rheumatoid Arthritis in the Ambulatory Setting
Irene Lazarus¹, Salahuddin Kazi², Alok Dwivedi³, Christopher Dodoo⁴ and Kanchan Pema⁵, ¹Internal Medicine, Texas Tech University Health Science Center, El Paso, TX, ²Rheumatology, UT Southwestern Medical Center, Dallas, TX, ³Biomedical Sciences Division of Biostatistics and Epidemiology, Texas Tech University Health Sciences Center, El Paso, TX, ⁴Texas Tech University Health Sciences Center, El Paso, TX, ⁵Internal Medicine/Rheumatology, Texas Tech University Health Science Center, El Paso, TX
Background/Purpose: Since 2008 the Center for Medicare and Medicaid Services (CMS) has been in the process of changing patient care to quality-valued healthcare. In order…
Abstract Number: 1560 • 2016 ACR/ARHP Annual Meeting
A Unique Immune Signature in Patients with Active Rheumatoid Arthritis but Normal C-Reactive Protein Levels: Potential for New Therapeutic Targets?
Claire Bradford¹, Rosa González-Serrano¹, Andrew Cole¹, Shashank Ramakrishnan¹, Giampiero Marra¹, Coziana Ciurtin², Elizabeth Jury¹ and Jessica Manson³, ¹Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom, ²Rheumatology Department, University College London, London, United Kingdom, ³Rheumatology Department, University College London Hospital, London, United Kingdom
Background/Purpose: Using musculoskeletal ultrasound (US) to assess joint erosions and disease activity in patients with seropositive rheumatoid arthritis (RA) an atypical subgroup was identified with…
Abstract Number: 1607 • 2016 ACR/ARHP Annual Meeting
The Development of a New Anti–Interleukin 6 Blocker for Rheumatoid Arthritis Patients
Alan Glicklich¹, Paul Grayson¹, Christophe Blanchetot², Qing Zhou³ and Anke Kretz-Rommel¹, ¹Bird Rock Bio, Inc, La Jolla, CA, ²Argenx, Ghent, Belgium, ³Genor BioPharma, Shanghai, China
Background/Purpose: While interleukin-6 (IL-6) blockade with monoclonal antibodies is an established, clinically validated mechanism for the treatment of rheumatoid arthritis (RA), the need for significant…
Abstract Number: 2161 • 2016 ACR/ARHP Annual Meeting
Association Between Inflammation and Systolic Blood Pressure at Normal and High C-Reactive Protein Levels
Zhi Yu¹, Kathleen Vanni², Seoyoung C. Kim³, Daniel H. Solomon⁴, Shawn N. Murphy⁵ and Katherine Liao⁶, ¹Rheumatology Immunology & Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Research Computing, Partners Healthcare Systems, Boston, MA, ⁶Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: While inflammation is linked with higher blood pressure (BP) in the general population, few studies have examined this relationship in patients with elevated levels…
Abstract Number: 342 • 2015 ACR/ARHP Annual Meeting
The Effect of Erosive Status on Systemic Inflammatory Biomarkers in Hand Osteoarthritis
Alexander Mathiessen¹, Nina Østerås², Tore K. Kvien³, Hilde Berner Hammer⁴ and Ida K. Haugen⁵, ¹Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²National Advisory Unit on Rehabilitation in Rheumatology, Department of Rheumatology,, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵P.O. Box 23, Diakonhjemmet Hospital, Vinderen, Norway
Background/Purpose : It is debated whether erosive hand osteoarthritis (OA) is a separate inflammatory subset of hand OA, or just a severe form of the same…
Abstract Number: 507 • 2015 ACR/ARHP Annual Meeting
Meta-Analysis of the Time Course of the Response to Adalimumab Plus Methotrexate or Methotrexate Monotherapy in Clinical Trials of Patients with Rheumatoid Arthritis
Xin Wang¹, Arthur Kavanaugh², Désirée van der Heijde³, Maxime Dougados⁴, Stefan Florentinus¹, Yihan Li¹, Iain Sainsbury¹ and Josef S. Smolen⁵, ¹AbbVie Inc., North Chicago, IL, ²University of California San Diego, La Jolla, CA, ³Leiden University Medical Center, Leiden, Netherlands, ⁴René Descartes University and Hôpital Cochin, Paris, France, ⁵Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Adalimumab (ADA) plus methotrexate (MTX) and MTX treatments for rheumatoid arthritis (RA) have been assessed in phase 2–4 clinical trials. This meta-analysis used 5…
Abstract Number: 714 • 2015 ACR/ARHP Annual Meeting
Baseline MRI and CRP As Predictors of Response to Etanercept in the Management of Patients with Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Matthew A. Brown¹, Paul A. Bird², Philip C. Robinson³, Philip J. Mease⁴, Filip van Den Bosch⁵, Christine Surian⁶, Zirke Wiid⁶, Heather Jones⁷, Annette Szumski⁸ and Lisa Marshall⁷, ¹Translational Research Institute, University of Queensland Diamantina Institute, Brisbane, Australia, ²University of New South Wales, Sydney, Australia, ³University of Queensland & Royal Brisbane and Women's Hospital, Brisbane, Australia, ⁴Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁵Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁶Pfizer Australia, Sydney, Australia, ⁷Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ⁸Department of Biostatistics, Pfizer, Collegeville, PA
Background/Purpose: Treatment with tumor necrosis factor α (TNFα) inhibitors has been shown to be effective in improving disease activity and functional capacity in patients with…
Abstract Number: 1527 • 2015 ACR/ARHP Annual Meeting
Serum Inflammation Identifies Increased Risk of Frailty in Rheumatoid Arthritis
James S. Andrews¹, Elizabeth R. Wahl², Gabriela Schmajuk³, Edward H. Yelin⁴ and Patricia P. Katz⁵, ¹Rheumatology, University of California San Francisco, San Francisco, CA, ²Medicine/Rheumatology, San Francisco Veterans Affairs Medical Center, San Francisco, CA, ³San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, ⁴University of California, San Francisco, San Francisco, CA, ⁵Rheumatology, UCSF, SF, CA
Background/Purpose: Frailty has been defined as “an excess vulnerability to stressors, with reduced ability to maintain or regain homeostasis after a destabilizing event” 1. Frailty…
Abstract Number: 2681 • 2015 ACR/ARHP Annual Meeting
Physical Function, Sleep, Depression but Not CRP Level Is Associated with Fatigue in Patients with Established Rheumatoid Arthritis
Yong Gil Hwang¹, Juan (June) Feng², Heather Eng², Jason Lyons², Anthony Fabio³ and Larry W. Moreland⁴, ¹Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ²Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ³Department Of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, ⁴Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Rheumatoid arthritis (RA) is characterized by inflammation of the joints and fatigue. Although many studies have identified risk factors for RA-associated fatigue, few studies…
Abstract Number: 534 • 2014 ACR/ARHP Annual Meeting
Serum Biomarkers of Inflammation and Fibrosis in Advancing Diagnosis, Prognosis and Treatment of Anti-Ro Associated Congenital Heart Block
Amit Saxena¹, Peter M. Izmirly², Sung Won Han³, Andrew Markham⁴, Robert M. Clancy⁵ and Jill P. Buyon⁵, ¹Rheumatology, New York University School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Department of Population Health, New York University School of Medicine, New York, NY, ⁴Medicine, New York University School of Medicine, New York, NY, ⁵Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose Women with Sjogren’s Syndrome (SS) and anti-Ro antibodies face the risk of a pregnancy complicated by fetal congenital heart block (CHB). Identification of maternal…
Abstract Number: 376 • 2014 ACR/ARHP Annual Meeting
Using the Multi-Biomarker Disease Activity Score As a Complementary Inclusion Criterion for Clinical Trials in Rheumatoid Arthritis May Enhance Recruitment
Ronald F. van Vollenhoven¹, Rebecca J. Bolce², Karen Hambardzumyan³, Saedis Saevarsdottir⁴, Kristina Forslind⁴, Ingemar Petersson⁵, Eric H. Sasso², CC Hwang⁶, Oscar Segurado² and Pierre Geborek⁷, ¹Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³ClinTRID, the Karolinska Institute, Stockholm, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁵Lund University, Department of Orthopedics, Clinical Sciences Lund, Lund, Sweden, ⁶Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA, ⁷Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose Clinical trials in rheumatoid arthritis (RA) often require elevated C-reactive protein (CRP) as an inclusion criterion, which may limit recruitment by excluding some patients…
Abstract Number: 2579 • 2014 ACR/ARHP Annual Meeting
How Should We Calculate the ASDAS If the Conventional C-Reactive Protein Is below the Limit of Detection? – an Analysis in the DESIR Cohort
Pedro Machado^1,2, Victoria Navarro-Compán^1,3, Robert Landewé^4,5, Floris van Gaalen¹, Christian Roux⁶ and Desirée van der Heijde¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²University College London, London, United Kingdom, ³University Hospital La Paz, Madrid, Spain, ⁴Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁵Atrium Medical Center, Heerlen, Netherlands, ⁶Paris Descartes University, Cochin Hospital, Paris, France
Background/Purpose: The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a composite measure of disease activity in axial spondyloarthritis. It was suggested that when the conventional …
Abstract Number: 2429 • 2014 ACR/ARHP Annual Meeting
Seasonal Changes May Influence Activity of Rheumatoid Arthritis
Ryuji Nagamine, Bone and Joint Center, Sugioka Memorial Hospital, Fukuoka, Japan
Background/Purpose: RA activity during the year was assessed to investigate whether seasonal changes influenced parameters of RA activity. Methods: This study was performed in Fukuoka,…
Abstract Number: 1621 • 2014 ACR/ARHP Annual Meeting
A Shift Towards Trans-Signalling Explains Relatively Low CRP Despite an Active Interleukin-6 (IL-6)/IL-6-Receptor (IL-6R) System in SLE
Martyna Skwarek, Babett Heschel, Julia Fantana and Martin Aringer, Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany
Background/Purpose IL-6 has been found increased in SLE, while CRP, which is directly stimulated by IL-6, usually remains low. We therefore analyzed the IL-6/ IL-6…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].